Yes - a pretty fair assessment. Must be recent, because Prof. Wiedermann gave her presentation in Sydney on June 16th (from memory). I was hoping to attend but couldn't get there. Her-Vaxx has enormous potential. Progression to Phase 11 trials late this year should see a major re-rate of IMU. Myself - I'm willing to hold longer, and see the Phase 11 results come in. If the trials reflect expectations - this will be a massively good investment. And sure - a bad result will sink it. That's the biotech business....
best wishes to all IMU investors and staff.
Dave
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.005(1.35%) |
Mkt cap ! $82.39M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.5¢ | 36.0¢ | $342.2K | 938.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 488 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 12566 | 2 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |